Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All paxlovid studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure Prophylactic Use

Pfizer, Press Release, NCT05047601
Apr 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Hospitalization, 10 day 67% Improvement Relative Risk Hospitalization, 5 day 67% Severe case, 10 day 25% Severe case, 5 day 22% Medical visit, 10 day 15% Medical visit, 5 day 3% Symp. case, 10 day, PCR- 36% Symp. case, 5 day, PCR- 30% Symp. case, 10 day 5% Symp. case, 5 day 27% Paxlovid  Pfizer et al.  Prophylaxis  DB RCT Is prophylaxis with paxlovid beneficial for COVID-19? Double-blind RCT 2,954 patients in multiple countries (Sep 2021 - Apr 2022) Lower severe cases (p=0.42) and progression (p=0.2), not sig. c19early.org Pfizer, Press Release, April 2022 Favors paxlovid Favors control
PEP RCT showing lower risk of cases with treatment, without statistical significance. Results from1.
risk of hospitalization, 66.5% lower, RR 0.33, p = 1.00, treatment 0 of 830 (0.0%), control 1 of 840 (0.1%), NNT 840, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), 10 day treatment.
risk of hospitalization, 66.7% lower, RR 0.33, p = 0.50, treatment 0 of 844 (0.0%), control 1 of 840 (0.1%), NNT 840, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), 5 day treatment.
risk of severe case, 25.2% lower, RR 0.75, p = 0.42, treatment 17 of 830 (2.0%), control 23 of 840 (2.7%), NNT 145, 10 day treatment.
risk of severe case, 22.1% lower, RR 0.78, p = 0.43, treatment 18 of 844 (2.1%), control 23 of 840 (2.7%), NNT 165, 5 day treatment.
medical visit, 15.3% lower, RR 0.85, p = 0.20, treatment 830, control 840, 10 day treatment.
medical visit, 3.1% lower, RR 0.97, p = 0.81, treatment 844, control 840, 5 day treatment.
risk of symptomatic case, 35.5% lower, RR 0.65, p = 0.12, treatment 830, control 840, 10 day treatment, PCR- at baseline.
risk of symptomatic case, 29.8% lower, RR 0.70, p = 0.17, treatment 844, control 840, 5 day treatment, PCR- at baseline.
risk of symptomatic case, 4.7% lower, RR 0.95, p = 0.82, treatment 887, control 873, 10 day treatment.
risk of symptomatic case, 27.4% lower, RR 0.73, p = 0.13, treatment 889, control 873, 5 day treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pfizer et al., 29 Apr 2022, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, preprint, 1 author, study period 9 September, 2021 - 12 April, 2022, trial NCT05047601 (history).
This PaperPaxlovidAll
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit